Collectively, these findings suggest that METTL16 modulates immune checkpoint signaling through m6A-dependent mechanisms, highlighting its potential role in shaping antitumor immunity and enhancing the therapeutic efficacy of ICIs in CRC (55). The gene discussed is METTL16; the disease is colorectal carcinoma.